|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Update on inflammatory bowel disease in patients with primary sclerosing cholangitis显示文摘Patients with primary sclerosing cholangitis(PSC) complicated by inflammatory bowel disease(IBD) represent a distinct subset of patients with unique characteristics,which have serious clinical implications.The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective.The prevalence of IBD,mainly ulcerative colitis in PSC patients is estimated to be 21%-80%,dependent on screening programs and nationality.PSC-associated colitis is likely to be extensive,characterized by rectal sparing,backwash ileitis,and generally mild symptoms.It is also more likely to progress to colorectal malignancy,making it imperative for clinicians to maintain a high level of suspicion when tackling PSC patients.There is no optimal surveillance strategy but current guidelines advocate that colonoscopy is necessary at the time of PSC diagnosis with annual endoscopic follow-up.Random biopsies have been criticized and a shift towards targeted biopsies using chromoendoscopy,laser endomicroscopy and narrow-band imaging has been noted.Techniques directed towards genetic mutations instead of histological abnormalities hold promise for easier,more accurate diagnosis of dysplastic lesions.Chemopreventive measures against colorectal cancer have been sought in these patients.Ursodeoxycholic acid seemed promising at first but subsequent studies yielded conflicting results showing anticarcinogenic effects in low doses(8-15 mg/kg per day) and carcinogenic properties in high doses(15-30 mg/kg per day). | Christos Tsaitas Anysia Semertzidou Emmanouil Sinakos | 2014 | World Journal of Hepatology2014，6，4： | 9 |
| 2 | Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?显示文摘Nonalcoholic fatty liver disease(NAFLD) is highly associated with insulin resistance(IR), type 2 diabetes mellitus and metabolic syndrome, being characterized as the hepatic component of metabolic syndrome. Despite its high prevalence, no pharmacological treatment has been established, as of yet. A growing body of evidence, however, shows that reducing IR can result in improvement of the biochemical and histological features of nonalcoholic steatohepatitis(NASH)-the aggressive form of NAFLD that can lead to cirrhosis and hepatocellular carcinoma. Unfortunately, the several trials that have assessed the effect of various antidiabetic agents to date have failed to establish an effective and safe treatment regimen for patients with NAFLD. Glucagon-like peptide-1(commonly known as GLP-1) agonists are a novel class of antidiabetic drugs that improve insulin sensitivity and promote weight loss. They also appear to have a direct effect on the lipid metabolism of hepatocytes, reducing hepatic steatosis. Several trials have demonstrated that GLP-1 agonists can reduce aminotransferase levels and improve liver histology in patients with NAFLD, suggesting that these agents could serve as an alternative treatment option for these patients. This manuscript discusses the role and potential mechanisms of GLP-1 agonists in the treatment of NASH. | Maria Kalogirou Emmanouil Sinakos | 2018 | World Journal of Hepatology2018，10，11： | 6 |
| 3 | Enhanced recovery after surgery in liver transplantation:Challenges and feasibility显示文摘BACKGROUND Enhanced recovery after surgery(ERAS)started a revolution that changed age-old surgical stereotypical practices regarding the overall management of the surgical patient.In the last decade,ERAS has gained significant acceptance in the community of general surgery,in addition to several other surgical specialties,as the evidence of its advantages continues to grow.One of the last remaining fields,given its significant complexity and intricate nature,is liver transplantation(LT).AIM To investigate the existing efforts at implementing ERAS in LT.METHODS We conducted a systematic review of the existing studies that evaluate ERAS in orthotopic LT,with a multimodal approach and focusing on measurable clinical primary endpoints,namely length of hospital stay.RESULTS All studies demonstrated a considerable decrease in length of hospital stay,with no readmission or negative impact of the ERAS protocol applied to the postoperative course.CONCLUSIONS ERAS is a well-validated multimodal approach for almost all types of surgical procedures,and its future in selected LT patients seems promising,as the preliminary results advocate for the safety and efficacy of ERAS in the field of LT. | Georgios Katsanos Konstantina-Eleni Karakasi Nikolaos Antoniadis Stella Vasileiadou Athanasios Kofinas Antonios Morsi-Yeroyannis Evangelia Michailidou Ioannis Goulis Emmanouil Sinakos Olga Giouleme Ilias Marios Oikonomou George Evlavis Georgios Tsakiris Eleni Massa Eleni Mouloudi Georgios Tsoulfas | 2022 | World Journal of Transplantation2022，12，7： | 3 |
| 4 | Colon Neoplasms Develop Early in the Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis显示文摘 | Erin W. Thackeray Phunchai Charatcharoenwitthaya Diaa Elfaki Emmanouil Sinakos Keith D. Lindor | 2011 | Clinical Gastroenterology and Hepatology2011，，1： | 2 |
| 5 | Update on the association of hepatitis B with intrahepatic cholangiocarcinoma:Is there new evidence?显示文摘Intrahepatic cholangiocarcinoma(iCCA)is a subgroup of cholangiocarcinoma that accounts for about 10%-20%of the total cases.Infection with hepatitis B virus(HBV)is one of the most important predisposing factors leading to the formation of iCCA.It has been recently estimated based on abundant epidemiological data that the association between HBV infection and iCCA is strong with an odds ratio of about 4.5.The HBV-associated mechanisms that lead to iCCA are under intense investigation.The diagnosis of iCCA in the context of chronic liver disease is challenging and often requires histological confirmation to distinguish from hepatocellular carcinoma.It is currently unclear whether antiviral treatment for HBV can decrease the incidence of iCCA.In terms of management,surgical resection remains the mainstay of treatment.There is a need for effective treatment modalities beyond resection in both first-and second-line treatment.In this review,we summarize the epidemiological evidence that links the two entities,discuss the pathogenesis of HBV-associated iCCA,and present the available data on the diagnosis and management of this cancer. | Nikolaos Fragkou Lazaros Sideras Panteleimon Panas Christos Emmanouilides Emmanouil Sinakos | 2021 | World Journal of Gastroenterology2021，27，27： | 2 |
| 6 | Bile acid profiles i-n intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatie cholestasis of pregnancy 显示文摘 | Sinakos E Lindor KD | 2010 | Am J Gastroenterol2010，105，3： | 1 |
| 7 | Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis:relation to disease progression显示文摘 | Sinakos E Marschall HU Kowdley KV | 2010 | Hepatology2010，52，1： | 1 |
| 8 | Gastrointestinal stomal tumors: a pictorial review显示文摘 | Chourmouzi D Sinakos E Papalavrentios L | 2009 | J Gastrointestin Liver Dis2009，18，3： | 1 |
| 9 | Gastrointestinal stromal tumors:a pictorial review 显示文摘 | CHOURMOUZI D SINAKOS E PAPALAVRENTIOS L | 2009 | J Gastroint-estin Liver Dis2009，18，3： | 1 |
| 10 | Bile acid profiles in intrahepatic chole- stasis of pregnancy : Is this the solution to the enigma of intrahe- patic cholestasis of pregnancy 显示文摘 | Sinakos E Lindor KD | 2010 | Am J Gastro-enterol2010，105，3： | 1 |
| 11 | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis 显示文摘 | Imam MH Sinakos E Gossard AA | 2011 | Aliment Pharmacol Ther2011，34，10： | 1 |
| 12 | Pathogenesis and management of pruritus in cholestatic liver disease 显示文摘 | Imam MH Gossard AA Sinakos E | 2012 | J Gastroenterol Hepatol2012，27，7： | 1 |
| 13 | Gastrointestina显示文摘 | Chourmouzi D Sinakos E Papalavrentios I | 2009 | JGas/roin/estin Liver Dis2009，18，12： | 1 |
| 14 | Gastrointestinal stromal tumors:a pictorial review显示文摘 | Chourmouzi D Sinakos E Papalavrentios L | | 0，，： | 1 |
| 15 | Gastrointestinal stromal tumors : a pictorial review显示文摘 | Chourmouzi D Sinakos E Papalavrentios L | 2009 | J Gastrointestin Liver Dis2009，18，3： | 1 |
| 16 | Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma显示文摘 | Imam MH Silveira MG Sinakos E | 2012 | Clin Gastroenterol Hepatol2012，10，2： | 1 |
| 17 | Pathogenesis and management of pruritus in cholestatic liver disease 显示文摘 | Imam MH Gossard AA Sinakos E el al | 2012 | J Gastroenterol Hepatol2012，27，7： | 1 |
| 18 | Epidemiology, Clinical Data, and Treatment of Viral Hepatitis in a Large Cohort of Intravenous Drug Users显示文摘 | Eleni Gigi Emmanouil Sinakos Albana Sykja Georgios Androulakis Christos Tanis Victoria Stayridou Effrosyni Tsirogianni Konstantinos Zouridakis Aristea-Lia Bellou Eleni Orfanou Maria Raptopoulou-Gigi | 2013 | Journal of Addiction Medicine2013，，1： | 1 |
| 19 | Pathogenesis and management of pruritus in cholestatic liver disease显示文摘 | Mohamad H Imam Andrea A Gossard Emmanouil Sinakos Keith D Lindor | 2012 | Journal of Gastroenterology and Hepatology2012，，7： | 1 |
| 20 | Pathogenesis and management of pruritus in cholestatic liver disease显示文摘 | Imam MH Gossard AA Sinakos E | 2012 | J Gastroenterol Hepatol2012，27，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员